Tumor microenvironment and molecular drivers in HCC

Case-Based Panel Discussion: Intermediate HCC/ advanced HCC: Immunotherapy for downstaging before Liver Transplantation

 Sub topics:

1. Current criteria for considering immunotherapy for downstaging in before Liver Transplantation?

2. Patients selection- how do you select patients who are most likely to respond to immunotherapy-based downstaging? What factors (tumor burden, AFP levels, MVI status, PS ) guide your decision-making?

3. What are the major immune-related adverse events (irAEs) associated with immunotherapy in the pre-Liver Transplantation setting? Especially focus on liver injury related to immunotherapy

4. Success rates of downstaging with immunotherapy Immunotherapy impact on Post Liver Transplantation outcomes and recurrence rate

5. Is there any role of combining Immunotherapy with loco regional therapy in downstaging of HCC for Liver Transplantation 6. Role of Dual IO, Is it better than single

Moderated Q&A